Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to find the highest dose of the investigational drug RMC-6236 that can be given safely in people with advanced solid tumors containing mutations in the KRAS gene. RMC-6236 targets the KRAS protein made by the mutated gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of cancer cells. RMC-6236 is taken orally (by mouth).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing the combination of sacituzumab govitecan and cetuximab for treating head and neck cancer. The people in this study have squamous cell cancer of the head and neck. Their cancer came back or spread after prior treatment.
The purpose of this study is to find the best dose of the drug selinexor that can be given safely with radiation therapy in young patients newly diagnosed with pediatric diffuse intrinsic pontine glioma (DIPG) or high-grade glioma. Researchers will also determine the effectiveness of combining selinexor with radiation therapy (given for eight weeks) followed by selinexor therapy alone for two years.
In this study, researchers are seeking to find the highest dose of the investigational drug BGB-16673 that can be given safely in people with lymphoma and other types of B cell cancers that have come back or continued to grow despite prior treatment. BGB-16673 degrades a protein called BTK, which helps B cells live and grow. By degrading BTK, BGB-16673 may stop or slow the growth and activity of B cells, which could lead to improvement in the symptoms associated with B cell cancers. BGB-16673 is taken orally (by mouth).
Researchers want to see if adding cryoablation to immunotherapy is better than immunotherapy alone for breast cancer. The people in this study have triple-negative breast cancer (TNBC) that has spread beyond its original site. The immunotherapy being studied is pembrolizumab.
Researchers want to find the best dose of TERN-701 to use in people with chronic myeloid leukemia (CML). The people in this study have CML that came back after treatment or could not be treated with standard therapies.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
